24 month-treatment with miglustat of three patients with Niemann-Pick disease type C: follow up using brain spectroscopy.

Abstract : Niemann-Pick C (NPC) is a fatal progressive neurolipidosis. Miglustat, an inhibitor of glycosphingolipid synthesis, has been proposed to treat patients but questions remain regarding its efficacy. A major problem has been the lack of suitable objective efficacy endpoints. Three adults with NPC were treated with miglustat for 24 months. Efficacy of treatment was assessed clinically and using brain magnetic resonance spectroscopy. All patients reported mild clinical improvement or stabilization. Furthermore, a sustained decrease in the choline/creatine ratio was observed in all three patients over time. Although these preliminary results require confirmation on a larger cohort of patients, they suggest that miglustat has some beneficial effect on brain dysfunction in NPC and that MRS could be used routinely as a non invasive surrogate marker of treatment efficacy.
Type de document :
Article dans une revue
Molecular Genetics and Metabolism, Elsevier, 2009, 96 (2), pp.55-8. 〈10.1016/j.ymgme.2008.10.002〉
Liste complète des métadonnées

https://hal.inria.fr/hal-00805433
Contributeur : Olivier Colliot <>
Soumis le : mercredi 27 mars 2013 - 19:21:09
Dernière modification le : mercredi 21 mars 2018 - 18:57:48

Identifiants

Collections

Citation

Damien Galanaud, Ayman Tourbah, Stéphane Lehéricy, Nathalie Leveque, Bénédicte Heron, et al.. 24 month-treatment with miglustat of three patients with Niemann-Pick disease type C: follow up using brain spectroscopy.. Molecular Genetics and Metabolism, Elsevier, 2009, 96 (2), pp.55-8. 〈10.1016/j.ymgme.2008.10.002〉. 〈hal-00805433〉

Partager

Métriques

Consultations de la notice

252